IRD Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -566.87% compared to Opus Genetics, Inc.'s net margin of -255.85%. Opus Genetics, Inc.'s return on equity of -490.41% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Opus Genetics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 243.8%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Opus Genetics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Opus Genetics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Opus Genetics, Inc. has a beta of 0.418, which suggesting that the stock is 58.186% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Opus Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Opus Genetics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Opus Genetics, Inc. quarterly revenues are $3.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Opus Genetics, Inc.'s net income of -$17.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Opus Genetics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opus Genetics, Inc. is 7.60x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -566.87% compared to Opus Genetics, Inc.'s net margin of --. Opus Genetics, Inc.'s return on equity of -490.41% beat Palatin Technologies's return on equity of --.

Opus Genetics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 243.8%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Opus Genetics, Inc., analysts believe Palatin Technologies is more attractive than Opus Genetics, Inc..

Opus Genetics, Inc. has a beta of 0.418, which suggesting that the stock is 58.186% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Opus Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opus Genetics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Opus Genetics, Inc. quarterly revenues are $3.1M, which are larger than Palatin Technologies quarterly revenues of --. Opus Genetics, Inc.'s net income of -$17.5M is higher than Palatin Technologies's net income of --. Notably, Opus Genetics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opus Genetics, Inc. is 7.60x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -566.87% compared to Opus Genetics, Inc.'s net margin of --. Opus Genetics, Inc.'s return on equity of -490.41% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Opus Genetics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 243.8%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that Theriva Biologics, Inc. has higher upside potential than Opus Genetics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Opus Genetics, Inc..

Opus Genetics, Inc. has a beta of 0.418, which suggesting that the stock is 58.186% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Opus Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opus Genetics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Opus Genetics, Inc. quarterly revenues are $3.1M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Opus Genetics, Inc.'s net income of -$17.5M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Opus Genetics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opus Genetics, Inc. is 7.60x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks, Inc. has a net margin of -566.87% compared to Opus Genetics, Inc.'s net margin of -70.99%. Opus Genetics, Inc.'s return on equity of -490.41% beat Zymeworks, Inc.'s return on equity of -18.82%.

Opus Genetics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 243.8%. On the other hand Zymeworks, Inc. has an analysts' consensus of $34.50 which suggests that it could grow by 30.09%. Given that Opus Genetics, Inc. has higher upside potential than Zymeworks, Inc., analysts believe Opus Genetics, Inc. is more attractive than Zymeworks, Inc..

Opus Genetics, Inc. has a beta of 0.418, which suggesting that the stock is 58.186% less volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.869%.

Opus Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Opus Genetics, Inc. pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.

Opus Genetics, Inc. quarterly revenues are $3.1M, which are smaller than Zymeworks, Inc. quarterly revenues of $27.6M. Opus Genetics, Inc.'s net income of -$17.5M is higher than Zymeworks, Inc.'s net income of -$19.6M. Notably, Opus Genetics, Inc.'s price-to-earnings ratio is -- while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Opus Genetics, Inc. is 7.60x versus 14.94x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.